Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 74

Results For "API"

3878 News Found

Sanofi appoints Dr Parikshit Chaudhari as Head of Market Access & Pricing Strategy
People | April 06, 2026

Sanofi appoints Dr Parikshit Chaudhari as Head of Market Access & Pricing Strategy

He brings extensive cross-functional expertise built through leadership roles


Experts advocate holistic Semaglutide use as therapy goes off patent in India
Healthcare | April 06, 2026

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market


Max Healthcare allots 57,461 equity shares under ESOP 2022
Hospitals | April 05, 2026

Max Healthcare allots 57,461 equity shares under ESOP 2022

Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees


Sun Pharma appoints former PwC India COO Satyavati Berera as independent director
Appointment | April 05, 2026

Sun Pharma appoints former PwC India COO Satyavati Berera as independent director

Board approves five-year appointment, subject to shareholder nod through postal ballot


Dr Jitendra Singh calls for India-led biosimilar insulin scale-up amid global supply concerns
Biotech | April 05, 2026

Dr Jitendra Singh calls for India-led biosimilar insulin scale-up amid global supply concerns

Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation


Cupid deposits Rs. 82.88 crore for strategic stake in Baazar Style Retail
News | April 05, 2026

Cupid deposits Rs. 82.88 crore for strategic stake in Baazar Style Retail

The deal gives Cupid immediate access to Style Baazar’s fast-growing network of over 260 stores


Innovent Biologics’ OLN324 shows breakthrough results in vision disease study
Biopharma | April 05, 2026

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred


Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib
Drug Approval | April 04, 2026

Cipla strengthens US respiratory portfolio with final FDA nod for generic Nintedanib

ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA


Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
Biopharma | April 03, 2026

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning


Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness
Clinical Trials | April 03, 2026

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year